ARWR ARROWHEAD PHARMACEUTICALS IN

2026Q1 · CUSIP 04280A100 · Sector: Healthcare & Biotech

Lit · Institutions accelerating in

Holders

432

Δ holders QoQ

+30

Breadth percentile

Top 10%

Whale holders

200

Δ whales

+10

Inst. holding value

$7.5B

New positions

103

Closed positions

Price momentum (1Q)

+16.1%

Put / Call

11/13

Breadth history (34 quarters)

Period	Percentile	Next-1Q return	Next-2Q return
2026Q1	Top 10%	—	—
2025Q4	Top 4%	+16.1%	—
2025Q3	Top 14%	+59.1%	+92.1%
2025Q2	Top 16%	+107.2%	+223.4%
2023Q2	Top 14%	-5.4%	+2.1%
2021Q2	Top 12%	+21.8%	-18.0%
2020Q4	Top 12%	-16.4%	-30.5%
2019Q4	Top 6%	-5.7%	+12.7%
2019Q3	Top 15%	-17.5%	-24.0%
2019Q2	Top 2%	+55.5%	+30.0%
2019Q1	Top 16%	+60.3%	+149.2%
2018Q4	Top 10%	+4.5%	+86.0%
2018Q3	Top 14%	+34.6%	+62.7%
2018Q2	Top 8%	-15.8%	+26.5%
2018Q1	Top 16%	+50.4%	+26.5%

Show all 15 events

Put holders

QoQ: +3

Call holders

QoQ: -1

See methodology →

PE (TTM)

—

EPS (TTM)

$-2.08

EPS YoY

—

Revenue (TTM)

$0.6B

Revenue YoY

+14.1%

Quarterly Revenue & EPS (4Y)

Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable

P/E (TTM) over time

P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden

As of 2026-03-31 · SEC filings (XBRL)